Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers estimate prevalence of SARS-CoV-2 antibodies among adults in orange county

Testing a representative sample of Orange County residents for a wide range of coronavirus antibodies, University of California, Irvine researchers found that 11.5 percent of them have antibodies for COVID-19, in contrast to previous estimates of less than 2 percent.

29 Oct 2020

Mouth may be primary route of SARS-CoV-2 infection and transmission

A new study published on the preprint server medRxiv in October 2020 shows that the virus also multiplies robustly in the oral cavity, indicating that saliva plays a role in viral transmission.

29 Oct 2020

REACT study shows 26% decline in SARS CoV-2 seroprevalence over 2-3 months

Their study titled, "Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults," was released online as a pre-print on the medRxiv* server. This large study was funded by the Department of Health and Social Care in England.

28 Oct 2020

Deep learning models help hunt for COVID-19 drugs

Michigan State University Foundation Professor Guowei Wei wasn't preparing machine learning techniques for a global health crisis. Still, when one broke out, he and his team were ready to help.

28 Oct 2020

Cost of Covid-19 tests plays key role in people’s willingness to undergo testing

Where and how long can schools remain open in times of the Corona pandemic? How safe are public transport means? Which rules must be observed when organizing events? To answer these questions, systematic tests for Corona infections and antibodies are of decisive importance.

28 Oct 2020

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Adaptate Biotherapeutics, a company focused on developing antibody-based therapeutics for modulation of gamma delta T cells, today announced the appointment of Stewart Kay as Chief Business Officer.

28 Oct 2020

Research finds a problem with concept of herd immunity in COVID-19

A recent study published on the preprint server medRxiv* in October 2020 suggests that arguments in favor of herd immunity are weakened by the fact that the steep increase in the number of COVID-19 deaths as a result of being exposed to the virus many times instead of once or a few times is not taken.

28 Oct 2020

Researchers demonstrate potent antibody that fights against coronavirus

Scientists at Fred Hutchinson Cancer Research Center in Seattle have shown that a potent antibody from a COVID-19 survivor interferes with a key feature on the surface of the coronavirus's distinctive spikes and induces critical pieces of those spikes to break off in the process.

28 Oct 2020

Furin cleavage site and D614G on SARS-CoV-2 spike evolved to balance infectivity, stability, cytopathicity

SARS-CoV-2 is the causative agent of COVID-19 disease, currently raging across the world. The virus has now infected more than 43.89 million individuals and claimed over 1.16 million lives. The study titled, "Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects," is released on the preprint server bioRxiv* in October 2020.

27 Oct 2020

Study: SARS-CoV-2 virus adopts new strategy to ensure its replication, spread

Since COVID-19 began its menacing march across Wuhan, China, in December 2019, and then across the world, the SARS-CoV-2 virus has taken a "whatever works" strategy to ensure its replication and spread.

27 Oct 2020

Impact of natural and vaccine-induced immunity could shape the future trajectory of COVID-19

New research suggests that the impact of natural and vaccine-induced immunity will be key factors in shaping the future trajectory of the global coronavirus pandemic, known as COVID-19.

27 Oct 2020

Researchers identify a new way to prevent skin reactions in cancer patients

Using the body's immune system to fight cancer has great potential, but can also bring serious side effects, including itchy and painful skin reactions.

27 Oct 2020

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

A recent study published on the preprint server bioRxiv* in October 2020 reports the development of a novel vaccine based on a simian adenoviral vector obtained from a group C gorilla isolate called GRAd32. This could help speed up vaccine development.

26 Oct 2020

Population-based COVID-19 prevalence surveys in Europe and Americas show risk of bias

A team of researchers from the Federal University of Health Sciences of Porto Alegre and the Federal University of Rio Grande do Sul performed a systematic review to assess these population-based COVID-19 prevalence surveys' reliability and biases qualitatively. Their study is published on the preprint server medRxiv.

26 Oct 2020

NRP-1 receptor potentiates SARS-CoV-2 infectivity

The COVID-19 pandemic is still actively spreading in many parts of the world, causing redoubled efforts to develop antivirals and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A recent study explores the role of a second type of cell surface receptor, called neuropilin, in the virus's entry into the host cell and its subsequent replication.

26 Oct 2020

Startling high SARS-CoV-2 seroprevalence in Veracruz, Mexico

A surprising new study published on the preprint server medRxiv in October 2020 reports a very high seroprevalence of IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the city of Vera Cruz, Mexico. They are among the highest to be reported anywhere in the world.

25 Oct 2020

Graphene-enhanced PPE for COVID-19

To tackle this need, nanotechnology researchers from Italy have suggested using bidimensional graphene to improve existing PPE kits. Their research is published on the preprint server medRxiv.

25 Oct 2020

Scientists devise new method to map HIV's sugary shield in unprecedented detail

Scientists from Scripps Research and Los Alamos National Laboratory have devised a method for mapping in unprecedented detail the thickets of slippery sugar molecules that help shield HIV from the immune system.

23 Oct 2020

Study: 90% of patients have detectable antibodies up to 7 months post contracting COVID-19

A new study led by Marc Veldhoen, principal investigator at Instituto de Medicina Molecular João Lobo Antunes (iMM; Portugal) with an interdisciplinary team of clinicians and researchers from Faculdade de Medicina da Universidade de Lisboa (FMUL) and Centro Hospitalar Lisboa Norte (CHLN) and collaborators at Instituto Português do Sangue e Transplantação (IPST), shows that 90% of subjects have detectable antibodies 40 days up to 7 months post contracting COVID-19.

23 Oct 2020